Last week, we provided an overview and analysis of the Federal Court of Canada’s review of new amendments to the Patented Medicines Regulations was released. With these regulations serving as the primary tool to regulate the price of pharmaceuticals in Canada, the implications of the new rules—and the Federal Court’s decision—are significant.
Those watching the industry are considering what it confirms about changes to Canada’s patent regime, what the government’s approach to pricing may be going forward in light of the new regulations, and what effect the decision could have on future appeals, including the upcoming appeal still to be heard in Québec.
Watch our intellectual property litigation team in their work-from-home conversation on what the ruling means:
Read our intellectual property team’s full bulletin on the Federal Court’s decision on the new Patented Medicines Regulations here.
To discuss these issues, please contact the author(s).
This publication is a general discussion of certain legal and related developments and should not be relied upon as legal advice. If you require legal advice, we would be pleased to discuss the issues in this publication with you, in the context of your particular circumstances.
For permission to republish this or any other publication, contact Janelle Weed.
© 2021 by Torys LLP.
All rights reserved.